CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …
The sense of stopping migraine prophylaxis
Introduction Migraine prophylactic therapy has changed over recent years with the
development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene …
development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene …
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
F Vernieri, N Brunelli, R Messina, CM Costa… - The Journal of …, 2021 - Springer
Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP)
pathway are effective and safe on migraine prevention. However, some drug agencies …
pathway are effective and safe on migraine prevention. However, some drug agencies …
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
J Schoenen, A Van Dycke, J Versijpt… - The Journal of Headache …, 2023 - Springer
The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …
Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
LF Iannone, D Fattori, S Benemei… - European Journal of …, 2022 - Wiley Online Library
Background and purpose Guidelines for migraine prophylaxis suggest stopping medication
after 6–12 months to reevaluate treatment appropriateness. The Italian Medicines Agency …
after 6–12 months to reevaluate treatment appropriateness. The Italian Medicines Agency …
The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …
Switching anti-CGRP (R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study
LF Iannone, A Burgalassi, G Vigani, G Tabasso… - …, 2023 - journals.sagepub.com
Background A pharmacological class effect was initially proposed for monoclonal antibodies
against the calcitonin gene related peptide pathway. However, preliminary evidence shows …
against the calcitonin gene related peptide pathway. However, preliminary evidence shows …
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
N Vandenbussche, K Pisarek, K Paemeleire - The Journal of Headache …, 2023 - Springer
Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
F Vernieri, N Brunelli, S Guerzoni, LF Iannone… - Journal of …, 2023 - Springer
Background The outcome of migraine patients retreated with monoclonal antibodies (mAbs)
targeting the calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr) is not …
targeting the calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr) is not …
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP (− receptor) antibodies
M Terhart, J Mecklenburg, L Neeb, LH Overeem… - The Journal of …, 2021 - Springer
Background Migraine preventive treatment with CGRP (− receptor) monoclonal antibodies
(mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German …
(mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German …